Cytotoxic anticancer agents are designed to kill tumor cells by interfering with cell division mechanisms. In contrast, non-cytotoxic anticancer agents intend to inhibit cancer growth by targeting specific proteins or signaling pathways or by activating the immune system. We investigated whether these different modes of action are reflected in study designs, objectives and results of Phase I studies.
Comparison of study designs, objectives and results of Phase I trials with cytotoxic versus non-cytotoxic anticancer agents

Featured Content

Blog
ICH E11A: Key Features and Implications of the Pediatric Extrapolation Guideline
Read More

Infographic
Shifting Frontiers: The Expansion of Cell & Gene Therapies into Autoimmune Disease
Read More

Blog
Rare Disease Clinical Trials: Challenges, Strategies, and Solutions for Success
Listen Now
View All Resources